



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication: Myelodysplastic Syndrome(MDS)**

1. Drug Response Prediction

Therapies of Interest	Patient Predicted Response
AZACITIDINE	Responder
DECITABINE	Responder
LENALIDOMIDE	Non-Responder

\*For more details of actionable molecular target(s) and pathway(s), please check this [link](#).

2. Patient Disease Characteristics: Key Biomarker(s)

PARP1	AURKB
CHEK2	TP53
CHEK1	PPARG
CSNK2A1	
MYC	

\*For more details on selected biomarker(s) and its impact on patient's disease profile, please check this [link](#).

3. Biomarker Impact Score

Therapies of Interest	Patient Biomarker Characteristics							
	PARP1	CHEK2	CHEK1	CSNK2A1	MYC	AURKB	TP53	PPARG
AZACITIDINE	✓			✓	✓	✓	✓	
DECITABINE	✓			✓	✓	✓	✓	
LENALIDOMIDE	✓				✓	✓		

The Cellworks proprietary workflow solution used to generate this test report from patient's medical records (Test Report), has not been approved by any regulatory or medical authority. Cellworks generated information is adjunctive information to physicians and molecular tumor boards. CELLWORKS DOES NOT ASSURE OR GUARANTEE THE SUCCESS OF ANY THERAPEUTIC OPTION IDENTIFIED IN THIS TEST REPORT. The user of this Test Report remains responsible for the conduct of patient care and for evaluating the clinical relevance of information provided by the prediction software. Cellworks is not an entity licensed to practice medicine or clinical activity and the Test Report generated by Cellworks does not amount to, or substitute, qualified professional medical advice.



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication: Myelodysplastic Syndrome(MDS)**

4. Summary of Patient Genomic Profile

Input Data Type	Mutations, CNV and Cytogenetics
Genetic Mutation(s)	5
Copy Number Variation(s)	373
Gene(s) Methylated	0

4.1 Detailed Information of Genomic Aberration(s) Modeled

4.1.1 Gene Mutation(s) with Gain of Function

NCOR1	PTPN11	TCF7L2
-------	--------	--------

4.1.2 Gene Mutation(s) with Loss of Function

KMT2C	MSH6
-------	------

4.1.3 Gene(s) with Increase in Copy Number Variation [CNV]

ABHD12	ABHD16A	ACSS1	ADRM1	AGER	ALG12	ANGPT1	ANGPT2
ARHGAP8	ASAHI	ASH2L	ATP6VIH	BAALC	BAG4	BIK	BLK
CCNE2	CDC25B	CEBPD	CERK	CHKB	CLU	CNOT7	COPS5
CSGALNACT1	CSNK2A1	CSNK2B	CTSB	CYP7A1	DDR1	DDX39B	DEPTOR
DERL1	DGATI	DHX16	DLC1	DPYS	E2F5	EGR3	EHMT2
EIF3E	EIF3H	EIF4EBP1	ELP3	EPHX2	ESRP1	EYA1	FABP5
FBXO32	FBXO43	FDFT1	FGFR1	FKBP1A	FKBPL	FNTA	FOXA2
GATA4	GFRA2	GFRA4	GGH	GPT	GSR	GTSE1	GZF1
HAS2	HDAC10	HEY1	HSF1	ID1	IDH3B	IDO1	IDO2
IKBKB	IL7	JAG1	KAT6A	LAMA5	LOXL2	LPL	LTA



**SINGULA™**  
**PRECISION MEDICINE**

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication: Myelodysplastic Syndrome(MDS)**

LTB	LY96	LYN	LYPLA1	MAPK11	MAPK12	MAVS	MCM4
MDC1	MICA	MICB	MMP16	MTDH	MYC	NBN	NCOA2
NDRG1	NEIL2	NOTCH4	NRG1	NSFL1C	NSMAF	NUDT18	OPLAH
PAG1	PBK	PCNA	PDLIM2	PDP1	PIM3	PLAT	PLCB1
PLXNB2	POLB	POU5F1	PPARA	PPP2R2A	PREX2	PRKDC	PRNP
PRR5	PSMA7	PTDSS1	PTK2	PTK2B	PTP4A3	RAB2A	RAD21
RALGAPA2	RASSF2	RB1CC1	RBCK1	RGS19	RIPK2	RRM2B	RUNX1T1
SCO2	SCRIB	SDC2	SFRP1	SFTPC	SGK3	SIRPA	SLC23A2
SLC25A32	SLC2A4RG	SNAI2	SNAP25	SPTLC3	SQLE	SRXN1	ST3GAL1
STK3	TASP1	TCEA1	TNF	TNFRSF10A	TNFRSF10B	TNFRSF10C	TNFRSF10D
TNFRSF11B	TRIB3	TRIM26	TYMP	UBR5	WNT7B	WRN	XKR4
XKR9	YWHAZ	ZDHHC2	ZFPM2	ZNF703			

**4.1.4 Gene(s) with Decrease in Copy Number Variation [CNV]**

ABCB1	ABCB5	ACSS2	ACTB	ADA	ADCY1	ADCYAPIR1	AHCY
AHR	AKAP9	AKR1B10	ARPC1A	ASB4	ASL	ASNS	ATG9B
AURKA	B4GALT5	BAZ1B	BCL7B	BHLHA15	BLVRA	BRAF	CAMK2B
CARD11	CASP2	CAV1	CCL26	CD36	CD40	CDK5	CDK6
CEBPB	CHN2	CLDN4	CNOT4	COL1A2	COPS6	CREB3L2	CUL1
CUX1	CYCS	CYP24A1	CYP51A1	DAGLB	DBF4	DDC	DGKB
DGKI	DMTF1	DNAJB6	DNAJB9	DNMT3B	DOCK4	DSN1	E2F1
EGFR	EIF2S2	EIF3B	ELMO1	ELMO2	EPB41L1	EPHA1	EPHB4
EPHB6	EPO	ETV1	EXOC4	EZH2	FSCN1	FZD1	FZD9
GGCT	GGT7	GLI3	GRB10	GSS	GSTK1	GTF2I	HBP1
HDAC9	HGF	HIPK2	HNF4A	HNRNPA2B1	HOXA1	HOXA10	HOXA11



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication: Myelodysplastic Syndrome(MDS)**

HOXA13	HOXA3	HOXA5	HOXA7	HOXA9	HSPB1	HTR5A	HUS1
IGFBP1	IGFBP3	IKZF1	IL6	IMPDH1	INSIG1	ITCH	ITGB8
L3MBTL1	LAMB1	LBP	LEP	LIMK1	MAD1L1	MAFB	MAFK
MAGI2	MCM7	MDH2	MET	MIOS	MIR182	MIR29A	MIR29B1
MLXIPL	MMP9	MNX1	MYBL2	NAMPT	NCF1	NCOA3	NCOA6
NDRG3	NFATC2	NOS3	NRF1	NUDT1	NUP205	OGDH	PAXIP1
PDGFA	PDIA4	PDK4	PHF20	PIK3CG	PLCG1	PMS2	PODXL
POLD2	POLM	PPP1R3A	PREX1	PRSS1	PSMA2	PSMC2	PSMG3
PSPH	PTGIS	PTN	PTPN1	PTPRZ1	RAC1	RALA	RASA4
RBL1	RHEB	RPA3	SAMHD1	SDC4	SEC61G	SEMA3E	SERPINE1
SFRP4	SH2B2	SHH	SLA2	SLC29A4	SMO	SMURF1	SNAI1
SNX13	SRC	SRPK2	STEAP1	STEAP4	STK4	STX1A	TBXAS1
TFPI2	TOP1	TRIM24	TWIST1	UBE3C	UPP1	USP42	VIPR2
WASL	WEE2	WIPI2	WISP2	XRCC2	ZC3HC1	ZDHHC4	ZNF217



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication: Myelodysplastic Syndrome(MDS)**

**5. Therapy Rationale(s)**

Rationales provided in this section highlight the pathways connected to drug sensitivity and resistance and include references to supporting published literature.

Species in **red** denote drug impact points. Species highlighted in **blue** are the key biomarkers.

STATUS: **GOF:** Gain of Function Mutations; **LOF:** Loss of Function Mutations; **SOF:** Switch of Function Mutations; **AMP:** CNV Over-expression; **DEL:** CNV Knock-down;

TYPE: **R:** Resistant Gene/Loop for the Drug; **S:** Sensitive Gene/Loop for the Drug

AZACITIDINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	DEL	R	<p>AZACITIDINE —  DNMT1 —&gt; CPGMET</p> <p>EZH2 —&gt; PRC2_COMPLEX —&gt; CPGMET</p>	19194470 16357870
GGH	AMP	R	<p>AZACITIDINE —  DNMT1 —&gt; CPGMET</p> <p>GGH —  S ADENOSYL METHIONINE —&gt; CPGMET —  TP53 —  CANCER PROGRESSION</p> <p>GGH —  S ADENOSYL METHIONINE —&gt; CPGMET —  CDKN1A —  CSNK2A1 —&gt; API —&gt; CTNNB1 —&gt; CANCER PROGRESSION</p> <p>GGH —  S ADENOSYL METHIONINE —&gt; CPGMET —  DUSP6 —  MAPK1 —&gt; MYC —&gt; CANCER PROGRESSION</p> <p>GGH —  S ADENOSYL METHIONINE —&gt; CPGMET —  CDKN1A —  CSNK2A1 —&gt; HDAC1 —  RUNX3 —  CANCER PROGRESSION</p> <p>GGH —  S ADENOSYL METHIONINE —&gt; CPGMET —  TP53 —  PTK2 —&gt; CANCER PROGRESSION</p> <p>GGH —  S-ADENOSYL METHIONINE —&gt; CPGMET —  CDKN1A —  CSNK2A1 —&gt; API —&gt; CTNNB1 —&gt; CANCER PROGRESSION</p> <p>GGH —  S-ADENOSYL METHIONINE —&gt; CPGMET —  CDKN1A —  CSNK2A1 —&gt; HDAC1 —  RUNX3 —  CANCER PROGRESSION</p>	12154409 25502219 25886188 23647960 12579297 12799639 19417127 15867363 12689679 7626805 11255227 1516134 17146436 23612983 17935135 18850007 12383256 23671287 25224413 19142899 28928282 22617422 21858223 15824892 19363521



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication:** Myelodysplastic Syndrome(MDS)

AZACITIDINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
KAT6A	AMP	S	AZACITIDINE —  DNMT1 —  CPGMET	
			KAT6A —  EZH2 —  DNMT1 —  CPGMET —  TP53 —	
			CANCER PROGRESSION	
			KAT6A —  EZH2 —  DNMT1 —  CPGMET —  CDKN1A	12154409 25772242
			—  CSNK2A1 —  API —  CTNNB1 —  CANCER	16357870 25886188
			PROGRESSION	
			KAT6A —  EZH2 —  DNMT1 —  CPGMET —  DUSP6	23647960 12579297
			—  MAPK1 —  MYC —  CANCER PROGRESSION	12799639 19417127
			KAT6A —  EZH2 —  DNMT1 —  CHEK1 —  AURKB —	15867363 12689679
			SPI —  CANCER PROGRESSION	
			KAT6A —  EZH2 —  PRC2_COMPLEX —  CPGMET —	7626805 11255227
			CDKN1A —  CSNK2A1 —  HDAC1 —  RUNX3 —  CANCER	1516134 17146436
			PROGRESSION	
			KAT6A —  EZH2 —  PRC2_Complex —  CPGMET —	23612983 17935135
			CDKN1A —  CSNK2A1 —  API —  CTNNB1 —  CANCER	18850007 23671287
			PROGRESSION	
			KAT6A —  EZH2 —  PRC2_Complex —  CPGMET —	20097731 16850502
			CDKN1A —  CSNK2A1 —  HDAC1 —  RUNX3 —  CANCER	22461507 20823107
			PROGRESSION	
			KAT6A —  EZH2 —  PRC2_COMPLEX —  CPGMET —	19923321 8285455
			CDKN1A —  CSNK2A1 —  HDAC1 —  RUNX3 —  CANCER	10400703 28536097
			PROGRESSION	
			KAT6A —  EZH2 —  PRC2_COMPLEX —  CPGMET —	11304577 27703524
			CDKN1A —  CSNK2A1 —  API —  CTNNB1 —  CANCER	10676641 22569363
			PROGRESSION	
			KAT6A —  EZH2 —  PRC2_COMPLEX —  CPGMET —	14532106 19142899
			TP53 —  CANCER PROGRESSION	
			KAT6A —  EZH2 —  PRC2_COMPLEX —  CPGMET —	28928282 16407820
			CDKN1A —  CSNK2A1 —  SNAI1 —  CANCER PROGRESSION	21858223 17015478
			KAT6A —  EZH2 —  PRC2_COMPLEX —  CPGMET —	26498513 15824892
DUSP6 —  MAPK1/3 —  MYC —  CANCER PROGRESSION	24647617 29487290			
KAT6A —  EZH2 —  PRC2_COMPLEX —  CPGMET —	19363521 9261115			
PTEN —  PTK2 —  TP53 —  CANCER PROGRESSION	24688109 22024163			
KAT6A —  EZH2 —  PRC2_COMPLEX —  DNMT1 —				
CPGMET —  CDKN1A —  CSNK2A1 —  API —  CTNNB1				
—  CANCER PROGRESSION				
KAT6A —  EZH2 —  PRC2_COMPLEX —  DNMT1 —				
CPGMET —  CDKN1A —  CSNK2A1 —  HDAC1 —  RUNX3				
—  CANCER PROGRESSION				



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication:** Myelodysplastic Syndrome(MDS)

AZACITIDINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
			<b>AZACITIDINE</b> —  <b>DNMT1</b> —  <b>CPGMET</b> <b>AZACITIDINE</b> —  <b>DNMT1</b>	
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>PRC2_COMPLEX</b> —  <b>CPGMET</b> —  <b>CDKN1A</b> —  <b>CSNK2A1</b> —  <b>API1</b> —  <b>CTNNB1</b> —  <b>CANCER PROGRESSION</b>	12154409 23671287 17540172 16357870
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>PRC2_COMPLEX</b> —  <b>CPGMET</b> —  <b>DUSP6</b> —  <b>ERK</b> —  <b>MYC</b> —  <b>CANCER</b> <b>PROGRESSION</b>	23647960 19417127 20097731 15824892
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>DNMT1</b> —  <b>CPGMET</b> —  <b>CDKN1A</b> —  <b>CSNK2A1</b> —  <b>API1</b> —  <b>CTNNB1</b> —  <b>CANCER</b> <b>PROGRESSION</b>	22461507 28445985 23979523 9261115
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>DNMT1</b> —  <b>CPGMET</b> —  <b>CDKN1A</b> —  <b>CSNK2A1</b> —  <b>HDAC1</b> —  <b>RUNX3</b> —  <b>CANCER</b> <b>PROGRESSION</b>	16407820 25886188 12579297 12799639
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>DNMT1</b> —  <b>CPGMET</b> —  <b>TP53</b> —  <b>CANCER PROGRESSION</b>	15867363 12689679 7626805 1516134
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>DNMT1</b> —  <b>CPGMET</b> —  <b>DUSP6</b> —  <b>MAPK1</b> —  <b>MYC</b> —  <b>CANCER PROGRESSION</b>	17146436 23612983 18850007 27703524
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>DNMT1</b> —  <b>CHEK1</b> —  <b>AURKB</b> —  <b>SP1</b> —  <b>CANCER PROGRESSION</b>	14532106 10676641 17015478 28928282
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>PRC2_COMPLEX</b> —  <b>CPGMET</b> —  <b>TP53</b> —  <b>CANCER PROGRESSION</b>	22024163 19363521
			<b>L3MBTL1</b> —  <b>E2F1</b> —  <b>EZH2</b> —  <b>DNMT1</b> —  <b>CPGMET</b> —  <b>DUSP6</b> —  <b>MAPK1</b> —  <b>MYC</b> —  <b>HK2</b> —  <b>CANCER</b> <b>PROGRESSION</b>	
L3MBTL1	DEL	S		



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication:** Myelodysplastic Syndrome(MDS)

DECITABINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
KAT6A	AMP	S	DECITABINE —  DNMT1 —> CPGMET	12154409 25772242
			KAT6A —> EZH2 —> PRC2_COMPLEX —> CPGMET —	16357870 25886188
			CDKN1A —  CSNK2A1 —> HDAC1 —  RUNX3 —	23647960 12579297
			CANCER PROGRESSION	12799639 19417127
			KAT6A —> EZH2 —> DNMT1 —> CPGMET —  TP53	15867363 12689679
			—  CANCER PROGRESSION	7626805 11255227
			KAT6A —> EZH2 —> DNMT1 —> CPGMET —  CDKN1A	1516134 17146436
			—  CSNK2A1 —> API —> CTNNB1 —> CANCER	23612983 17935135
			PROGRESSION	18850007 23671287
			KAT6A —> EZH2 —> DNMT1 —> CPGMET —  DUSP6	20823107 19923321
			—  MAPK1 —> MYC —> CANCER PROGRESSION	16850502 21248841
			KAT6A —> EZH2 —> DNMT1 —> CHEK1 —> AURKB	28869966 11668500
			—> SP1 —> CANCER PROGRESSION	27073531 18311148
			KAT6A —> EZH2 —> PRC2_COMPLEX —> CPGMET —	17325427 11327722
			CDKN1A —  CSNK2A1 —> API —> CTNNB1 —> CANCER	19142899 22461507
			PROGRESSION	28928282 11602581
			KAT6A —> EZH2 —> PRC2_COMPLEX —> CPGMET —	16861352 21858223
			CDKN1A —  CSNK2A1 —> HDAC1 —  RUNX3 —	17015478 26516376
			CANCER PROGRESSION	15824892 26791049
			KAT6A —> EZH2 —> PRC2_COMPLEX —> CPGMET —	22343522 21709715
CDKN1A —  CSNK2A1 —> SNAI1 —> CANCER PROGRESSION	7556187 24389641			
KAT6A —> EZH2 —> PRC2_COMPLEX —> DNMT1 —>	10801130 19363521			
CPGMET —  CDKN1A —  CSNK2A1 —  API —> CTNNB1	24688109 28261562			
—> CANCER PROGRESSION	24058769 22024163			
KAT6A —> EZH2 —> PRC2_COMPLEX —> DNMT1 —>				
CPGMET —  CDKN1A —  CSNK2A1 —> HDAC1 —				
RUNX3 —  CANCER PROGRESSION				





**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication:** Myelodysplastic Syndrome(MDS)

DECITABINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
L3MBTL1	DEL	S	<b>DECITABINE</b> —  <b>DNMT1</b> <b>DECITABINE</b> —  <b>DNMT1</b> —> <b>CPGMET</b>	20097731 17540172
			L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>CDKN1A</b> —  <b>CSNK2A1</b> —> <b>API</b> —> <b>CTNNB1</b> —>	15824892 16407820
			CANCER PROGRESSION L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>CDKN1A</b> —  <b>CSNK2A1</b> —> <b>HDAC1</b> —  <b>RUNX3</b>	19417127 23647960
			CANCER PROGRESSION L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>DUSP6</b> —  <b>ERK</b> —> <b>MYC</b> —> <b>CANCER</b>	17015478 9261115
			PROGRESSION L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>DUSP6</b> —  <b>MAPK1</b> —> <b>MYC</b> —> <b>HK2</b> —>	16357870 12154409
			CANCER PROGRESSION L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>TP53</b> —  <b>CANCER PROGRESSION</b>	24389641 22461507
			L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>DUSP6</b> —  <b>MAPK1</b> —> <b>MYC</b> —> <b>CANCER</b>	28445985 14532106
			PROGRESSION L3MBTL1 —  E2F1 —> EZH2 —> <b>DNMT1</b> —> <b>CHEK1</b> —> <b>AURKB</b> —> <b>SPI</b> —> <b>CANCER PROGRESSION</b>	28928282 23671287
			<b>DECITABINE</b> —  <b>DNMT1</b> —> <b>CPGMET</b>	22024163 25886188
			EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>CDKN1A</b> —  <b>CSNK2A1</b> —> <b>API</b> —> <b>CTNNB1</b> —> <b>CANCER PROGRESSION</b>	23979523 19363521
			EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>CDKN1A</b> —  <b>CSNK2A1</b> —> <b>HDAC1</b> —  <b>RUNX3</b> —  <b>CANCER PROGRESSION</b>	12579297 12799639
			EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>TP53</b> —  <b>CANCER</b> PROGRESSION EZH2 —> <b>DNMT1</b> —> <b>CPGMET</b> —  <b>DUSP6</b> —  <b>MAPK1</b> —> <b>MYC</b> —> <b>CANCER PROGRESSION</b>	15867363 12689679
EZH2 —> <b>DNMT1</b> —> <b>CHEK1</b> —> <b>AURKB</b> —> <b>SPI</b> —>	7626805 1516134			
<b>CANCER PROGRESSION</b>	17146436 23612983			
	18850007			



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication:** Myelodysplastic Syndrome(MDS)

DECITABINE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
GGH	AMP	R	DECITABINE —  DNMT1 —> CPGMET	12154409 25502219
			GGH —  S ADENOSYL METHIONINE —> CPGMET —	25886188 23647960
			CDKN1A —  CSNK2A1 —> AP1 —> CTNNB1 —> CANCER PROGRESSION	12579297 12799639
			GGH —  S ADENOSYL METHIONINE —> CPGMET —	19417127 15867363
			CDKN1A —  CSNK2A1 —> HDAC1 —  RUNX3 —	12689679 7626805
			CANCER PROGRESSION	11255227 1516134
			GGH —  S ADENOSYL METHIONINE —> CPGMET —  TP53 —	17146436 23612983
			CANCER PROGRESSION	17935135 18850007
			GGH —  S ADENOSYL METHIONINE —> CPGMET —	19142899 28928282
			DUSP6 —  MAPK1 —> MYC —> CANCER PROGRESSION	22617422 21858223
			GGH —  S-ADENOSYL METHIONINE —> CPGMET —	22893792 25224413
			CDKN1A —  CSNK2A1 —> AP1 —> CTNNB1 —> CANCER PROGRESSION	15824892 23671287
GGH —  S-ADENOSYL METHIONINE —> CPGMET —	19363521 12383256			
CDKN1A —  CSNK2A1 —> HDAC1 —  RUNX3 —				
CANCER PROGRESSION				



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication:** Myelodysplastic Syndrome(MDS)

LENALIDOMIDE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EIF3E	AMP	S	<p><b>LENALIDOMIDE</b> → <b>CUL4-CRBN-DDB1-RBX1</b> —  <b>EIF3E</b></p> <p><b>EIF3E</b> → EIF4E → TRANSLATION → <b>MYC</b> → CANCER PROGRESSION</p> <p><b>EIF3E</b> → EIF4E → <b>MYC</b> → FOXM1 → CANCER PROGRESSION</p> <p><b>EIF3E</b> → EIF4E → TRANSLATION → <b>MYC</b> → IRF4 → CARD11-BCL10-MALT1 → IKBKG → CHUK_IKBKB → NFKB1 → CANCER PROGRESSION</p> <p><b>EIF3E</b> → EIF4E → TRANSLATION → <b>MYC</b> → IRF4 → CARD11-BCL10-MALT1 → IKBKG → CHUK_IKBKB → NFKB1 → CANCER PROGRESSION</p>	<p>25610725 25108355</p> <p>24914135 26668357</p> <p>26119939 25187272</p> <p>23243601 25833963</p> <p>16766523 15094766</p> <p>26152922 21389327</p> <p>24736843 15634685</p>
FNTA	AMP	S	<p><b>LENALIDOMIDE</b> → <b>CUL4-CRBN-DDB1-RBX1</b> —  <b>IKZF1</b></p> <p>FNTA → RAS → RAF → MAP2K1 → MAPK3 → <b>MYC</b> → MYC_MAX → <b>IKZF1</b> → IRF4 → CARD11 → MALT1 → BCL10 → IKBKB → NFKB1 → CANCER PROGRESSION</p> <p>FNTA → RAS → RAF → MAP2K1 → MAPK3 → <b>MYC</b> → <b>IKZF1</b> → IRF4 → CARD11 → MALT1 → BCL10 → IKBKB → NFKB1 → CANCER PROGRESSION</p>	<p>22552008 27899961</p> <p>22461507 28471446</p> <p>26269456 26668357</p> <p>25087226 16177281</p> <p>24002445 26119939</p> <p>22698399 25610725</p> <p>25043012 24914135</p> <p>10022904 10356400</p> <p>10747026 15125833</p> <p>17298882 17384642</p>



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication:** Myelodysplastic Syndrome(MDS)

LENALIDOMIDE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
MYC	AMP	S	LENALIDOMIDE → CUL4-CRBN-DDB1-RBX1 → IKZF1 → IRF4	25108355 25043012 18568025 25610725 22698399 24914135 9822609 22723949
			LENALIDOMIDE → CUL4-CRBN-DDB1-RBX1 → IKZF1/3 → IRF4 → MYC	
			LENALIDOMIDE → CUL4-CRBN-DDB1-RBX1 → IKZF1/3 → IRF4	
			LENALIDOMIDE → CUL4-CRBN-DDB1-RBX1 → IKZF1	
			MYC → MYC_MAX → IRF4 → IRF7 → IFNA → TYK2 → STAT1	29162862 26668357 26119939 25187272 23243601 25833963 26152922 10910100 21490621 15467722 11884587 21074711 25087226 26269456 24002445 22552008 28471446 20685844 28368411 15664995 12119358 25359993 18798339 28584182 10770796
			TYK2 → STAT3 → CANCER PROGRESSION	
			MYC → FOXM1 → CANCER PROGRESSION	
			MYC → IRF4 → IRF7 → IFNA → TYK2 → STAT1	
			→ CDKN1A → CANCER PROGRESSION	
			MYC → IRF4 → IRF7 → IFNA → TYK2 → STAT1	
			→ CDKN1A → CSNK2A1 → SNAI1 → CANCER PROGRESSION	
			MYC → IRF4 → IRF7 → IFNA → TYK2 → STAT1	
			→ CDKN1A → ROCK1 → CANCER PROGRESSION	
			MYC → IRF4 → CARD11 → BCL10 → MALTI → CHUK_IKBB → NFKB1 → CANCER PROGRESSION	
			MYC → IKZF1 → IRF4 → CARD11 → MALTI → BCL10 → IKBB → NFKB1 → CANCER PROGRESSION	
			MYC → MYC_MAX → IKZF1 → IRF4 → CARD11 → MALTI → BCL10 → IKBB → NFKB1 → CANCER PROGRESSION	
			MYC → IRF4 → IRF7 → IFNA → TYK2 → STAT1	
			→ CDKN1A → CDK2_CCNA2 → FOXM1 → CANCER PROGRESSION	
			MYC → IRF4 → CARD11-BCL10-MALTI → IKBKG → CHUK_IKBB → NFKB1 → CANCER PROGRESSION	



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication:** Myelodysplastic Syndrome(MDS)

LENALIDOMIDE				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
IKZF1	DEL	R	<p>LENALIDOMIDE → CUL4-CRBN-DDB1-RBX1 → IKZF1</p> <p>IKZF1 → MYC → CANCER PROGRESSION</p>	<p>25108355 25043012</p> <p>25610725 24914135</p> <p>29259013 26430725</p> <p>28471446 22698399</p> <p>24292625</p>
JAG1	AMP	R	<p>LENALIDOMIDE → CUL4-CRBN-DDB1-RBX1 → SPEN → NOTCH1</p> <p>JAG1 → NOTCH1 → MYC → CANCER PROGRESSION</p>	<p>12374742 24914135</p> <p>16847353 23940785</p>
KAT6A	AMP	S	<p>LENALIDOMIDE → CRBN → AMPK → TP53</p> <p>LENALIDOMIDE → CRBN → AMPK → TP53</p> <p>KAT6A → TP53 → PTK2 → CANCER PROGRESSION</p> <p>KAT6A → TP53 → CANCER PROGRESSION</p>	<p>28958290 25772242</p> <p>23431171 21232561</p> <p>15866171</p>



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication: Myelodysplastic Syndrome(MDS)**

6. Genomic Aberration to Key Biomarker Pathway(s)

This section provides a snapshot of paths connecting the most significant gene aberrations with patient biomarkers and references to published research supporting these pathways.

**RED:** Gain of Function/Switch of Function Mutation(s) or Amplified Gene(s)

**BLUE:** Loss of Function Mutation(s) or Deleted Gene(s)

TRANSCRIPTION FACTORS:

Key Biomarker(s)	Molecular Pathway Rationale for Biomarker(s)	Reference PMID(s)
TP53	CUX1 → ATM → BRCA1 → TP53	10373534 10550055 10783165 10866324 14701743 19377469 22319212 9582019
	KMT2C → TP53	19433796 22034226
PPARG	CUX1 → ATM → BRCA1 → CDKN1A → CSNK2A1 HDAC3 → PPARG	10373534 10550055 10783165 10866324 11255227 12479814 14701743 15832170 16127449 22319212 22850745 25101980
	KMT2C → PPARG	16029943
MYC	CUX1 → ATM → BRCA1 → CDKN1A → CSNK2A1 MYC	10373534 10550055 10783165 10866324 11255227 12149649 14701743 18438430 22319212 22850745 25101980 2663470
	L3MBTL1 → MYC	17540172
	RAD21 → MYC	28729862



**SINGULA™**  
PRECISION MEDICINE

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication: Myelodysplastic Syndrome(MDS)**

KINASE\*\*:

Key Biomarker(s)	Molecular Pathway Rationale for Biomarker(s)	Reference PMID(s)
CSNK2A1	CUX1 → ATM → BRCA1 → CDKN1A — CSNK2A1	10373534 10550055 10783165 10866324 11255227 14701743 22319212 22850745 25101980
AURKB	CUX1 → ATM → BRCA1 → CDKN1A — CSNK2A1 → HDAC3 → AURKB	10373534 10550055 10783165 10866324 11255227 14701743 19287963 22319212 22751009 22850745 25101980

\*\* Assayable key kinase biomarkers identified for this patient.



**SINGULA™**  
**PRECISION MEDICINE**

**Clinical ID:** XYZ98765

**Cellworks ID:** 445533

**Ref Physician:** Dr.White

**Biopsy Sequence:** 1

**Gender/Age:** Male / 65

**Date of Report:** Jul 22, 2019

**Indication: Myelodysplastic Syndrome(MDS)**

7. Terms of Usage

Cellworks Therapeutic Solutions

The Cellworks proprietary workflow solution used to generate this test report from patient's medical records (Test Report), has not been approved by any regulatory or medical authority. Cellworks generated information is adjunctive information to physicians and molecular tumor boards. CELLWORKS DOES NOT ASSURE OR GUARANTEE THE SUCCESS OF ANY THERAPEUTIC OPTION IDENTIFIED IN THIS TEST REPORT. The therapeutic options provided in the Test Report are not ranked in order of efficacy, safety or cost-effectiveness and are sorted based on our model's analysis of the input data. All individual drugs included in therapy options identified in the Test Report have been cleared and approved by the United States Food and Drug Administration (FDA) for other indications. At the specific request of the patient or treating physician, the Test Report may identify drugs or therapy options that are also in an advanced stage of clinical trials and yet to be approved. This will provide adjunctive information to the physicians for selecting a clinical trial for the patient.

Therapeutic agents associated with potential benefit or lack of benefit, as indicated in the Test Report are based on biomarker results provided in the report and on published evidence with PMID references. This evidence in some cases may have been obtained from studies performed in the cancer type present in the tested patient's sample.

No Guarantee of Clinical Benefit

The finding of a biomarker expression does not necessarily indicate pharmacologic effectiveness or lack thereof. The agents identified may or may not be suitable for use with a particular patient and the Test Report does not guarantee or suggest that any particular agent will be effective with the treatment of any particular condition. The user of this Test Report remains responsible for the conduct of patient care and for evaluating the clinical relevance of information provided by the prediction software.

Intended Use

Cellworks is not an entity licensed to practice medicine or clinical activity and the Test Report generated by Cellworks does not amount to, or substitute, qualified professional medical advice. THIS REPORT IS PREPARED AS ADJUNCTIVE INFORMATION TO ASSIST HEALTH CARE PROVIDERS TO EVALUATE THEIR PATIENTS. CELLWORKS IS NOT RESPONSIBLE FOR ANY USE OF THIS TEST REPORT OR DATA BY ANY UNQUALIFIED PERSON. Decisions on patient care and treatment, including safety and security of treatments based on this Test Report must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition and the treatment should not solely be based on this Test Report. Cellworks provides no guarantee of the accuracy, relevance, exhaustiveness or appropriateness of any of the medical information referenced through this Test Report.

CELLWORKS DISCLAIMS ALL WARRANTIES, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF TITLE, NON- INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, IN RELATION TO INTERFACE, ITS SERVICES AND THE TEST REPORT. CELLWORKS PROVIDES NO ASSURANCE OR GUARANTEE THAT A HEALTHCARE PROVIDER, INSURER OR ANY OTHER THIRD PARTY PAYOR, WHETHER GOVERNMENTAL OR PRIVATE, WILL REIMBURSE A PATIENT FOR THE COST OF GENERATING TEST REPORT.

This is an automatically generated report. No signature is required.  
--END OF THE REPORT--